Kasten, Inc. (OTC: KAST) Breaking News -
March 7, 2017
Kasten, Inc. Completes Merger with
Dakota Life Sciences
SILVER SPRINGS, NV - March 7, 2017 - Kasten, Inc. (OTC:
KAST) announced
today it has completed a merger with Thru Pharma LLC dba DAKOTA Life Sciences.
Upon review of Dakota during the phases of the JV setup, the Board of Directors
and Members of Kasten and Dakota determined it was in the best interests of both
entities and their stockholders to
consummate the merger of Kasten with and into Dakota with Kasten as the
surviving entity.
Dakota Life Sciences is engaged in developing innovative health products
utilizing Site Specific Penetration Technology SSPT™ technologies. These
products include but are not limited to Thin Nail® (OTC First Aid Nail
Antifungal), Symphony™ OTC First Aid Antibiotic, ThinNail® RX Topical
Antifungal, Symphony ™ RX Topical Antibiotic, Reserve ™ Rx Line of Topical
Antibiotics and an R&D pipeline of wound care and dermatology products, as well
as other valuable life sciences technologies.
Dakota Life Sciences is a leading anti-infectives private pharmaceutical Company
with award-winning products designed to provide the highest efficacy for global
patients at high risk of suffering from dangerous microbial and fungal
infections.
“Dakota Life Sciences is the solution to take Kasten to the next level. They
have a driven experienced management team and the product line already in place
to enhance shareholder value,” stated Jose Delgado, CEO of Kasten, Inc.
“Dakota Life Sciences is very pleased to combine forces with Kasten,” said the
President of Dakota Life Sciences, Steven Keough. “Our joint focus is to
introduce a range of high efficacy affordable prescription and OTC
pharmaceutical products that are unique to the market.”
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
_________________________________
Recent Kasten News:
Kasten, Inc. Provides
Shareholder Update on Status of Projects
SILVER SPRINGS, NV - January 19, 2017 - Kasten, Inc. (OTC:
KAST) updated its
shareholders today on the status of its pending projects.
On January 3, 2017, the Company announced a Joint Venture (JV) Agreement with
Dakota Life Sciences. The Company is in the process of setting up the JV in the
state of Nevada. Per the agreement, the name of the JV shall be KD Joint
Venture, Inc. and the purpose shall be to develop, fund, and market Site
Specific Penetration Technology (SSPT™) biopharmaceutical products.
DAKOTA Life Sciences has completed formulation development, validation, safety,
and efficacy testing on more than a dozen Over-The-Counter life sciences
products. Revenues from these proprietary products will commence soon, and will
be ongoing while the Company refines its prescription product regulatory
approval trials designs for several RX products. The combination of imminent OTC
revenue and near term Rx product revenue from high efficacy pharmaceuticals
creates several assets from which to drive investor value. The Rx products are
expected to receive FDA Fast Track designations, as they are focused on improved
delivery of known drugs - resulting in powerful efficacy improvements. This is
expected to dramatically reduce the risk, timing, and cost of these FDA approval
pathways. Qualified Infectious Disease Product designations will also be sought
for several of the Rx product approvals. This designation, once achieved, will
enable additional exclusivity for the designated products.
On December 2, 2016, the Company announced a letter of intent (LOI) with Gulf
Coast Pharmaceuticals to acquire formulas for Alzheimer's disease and Erectile
Dysfunction. As a result of its due diligence review, the Company has decided
not to pursue this opportunity.
"We are pleased with our go forward strategies to build shareholder value in an
industry that continues to show growth. Biotech drugs have steadily carved a
niche for themselves in the pharma market, and our plan is to capitalize on
specialty drugs and personalized medicine," stated Jose Delgado, CEO of Kasten,
Inc.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition,
development, and commercialization of medical therapies designed to prevent
and/or treat serious medical conditions. Kasten is principally focused on
delivering solutions to those medical conditions for which the care pathway is
burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
Kasten, Inc. Announces Signed
Joint Venture Agreement with Dakota Life Sciences
SILVER SPRINGS, NV - January 3, 2017 - Kasten, Inc. (OTC:
KAST) announced
today it has signed a Joint Venture agreement with Thru Pharma LLC dba DAKOTA
Life Sciences for the purpose of promoting the development and marketing of Site
Specific Penetration Technology (SSPT™ ) biopharmaceutical products.
Dakota Life Sciences is engaged in developing innovative health products
utilizing SSPT™ technologies. These products include but are not limited to Thin
Nail® (OTC First Aid Nail Antifungal), Symphony OTC First Aid Antibiotic,
ThinNail® RX Topical Antifungal, Symphony ™ RX Topical Antibiotic, Reserve ™ Rx
Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology
products, as well as genomics-based companion diagnostics.
Under the terms of the Joint Venture Agreement, both parties will have equal
ownership rights. "This new joint venture is uniquely positioned to optimize the
development of DAKOTA's biopharmaceutical product line. Together we will launch
their portfolio of products to the market place. This JV further compliments our
roll-up strategy of developing and commercializing innovative medical
solutions," stated Jose Delgado, CEO of Kasten, Inc.
DAKOTA Life Sciences is a leading anti-infectives private pharmaceutical Company
with award-winning products designed to provide the highest efficacy for global
patients at high risk of suffering from dangerous microbial and fungal
infections.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition,
development, and commercialization of medical therapies designed to prevent
and/or treat serious medical conditions. Kasten is principally focused on
delivering solutions to those medical conditions for which the care pathway is
burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
Kasten, Inc. Announces Signed
Term Sheet to Joint Venture with a Leading Medical Research Firm
SILVER SPRINGS, NV - December 15, 2017 - Kasten, Inc. (OTC:
KAST) announced
today it has signed a term sheet to joint venture with Pettersson Adams Medical
Research.
Pettersson is engaged in developing innovative health products utilizing unique
and patented technologies. They have developed a technology designed to treat
and reverse the plaques that accumulate in the brain thus enhancing the quality
of life, the cognitive functions of the brain and improving overall brain
health. The technology is centered and targeted on the delivery of compounds
both transdermal and transintestinal. The technology developed by Pettersson not
only treats the symptoms but also addresses the environment in the body that
causes the symptoms.
Plaques in the brain can not only lead to brain abnormality but death.
Intracranial stenosis is a narrowing of an artery inside the brain. A buildup of
plaque (atherosclerosis) inside the artery wall reduces blood flow to the brain.
Atherosclerosis that is severe enough to cause symptoms carries a high risk of
stroke and can lead to brain damage and death. In addition, one of the hallmarks
of Alzheimer's disease is the accumulation of amyloid plaques between nerve
cells (neurons) in the brain. The technology developed by Pettersson to treat
and reverse plaques that accumulate in the brain has the potential to save
millions of lives and provide hope to those that are suffering with Alzheimer's
disease and dementia.
Both parties have 45 days to conduct and complete due diligence. Upon successful
due diligence testing, Kasten believes it can create and maintain a successful
marketing program to introduce the technology to the marketplace. The companies
are also exploring a distribution agreement.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition,
development, and commercialization of medical therapies designed to prevent
and/or treat serious medical conditions. Kasten is principally focused on
delivering solutions to those medical conditions for which the care pathway is
burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
-------------------------------------------------------------------
About Kasten, Inc. (OTC: KAST):
About Kasten
Kasten, Inc. OTC: KAST is a biopharmaceutical company focused on the
acquisition, development, and commercialization of pharmaceuticals and devices
designed to prevent and treat serious conditions arising in the hospital and
adjacent clinical settings.
We are principally focused on delivering solutions to those wards in which the
care pathway is burdened by high morbidity, mortality, and cost. Our initial
goal is to market the first-in-class in situ product for the prevention of
surgical site infections in abdominal surgeries.
Our Mission
Focused Determination
A biopharmaceutical company focused on the acquisition, development, and
commercialization of pharmaceuticals and
devices designed to prevent and treat serious conditions arising in the hospital
and adjacent clinical settings.
Goal Driven
Our initial goal is to market the first in class in situ product for the
prevention of surgical site infections in abdominal surgeries.
True Solutions
We will be principally focused on delivering solutions to those wards in which
the care pathway is burdened by high morbidity, mortality, and cost.
Logical Strategy
In addition to clinical data, our solutions will be measured by condition, and
will be those metrics that matter to patients and providers.
SOURCE: http://kastenbiopharma.com/
Disclaimer
FN Media Group LLC (FNMG) owns and operates
FinancialNewsMedia.com (FNM)
which is a third party publisher that disseminates electronic information
through multiple online media channels. FNMG's intended purposes are to deliver
market updates and news alerts issued from private and publicly trading
companies as well as providing coverage and increased awareness for companies
that issue press to the public via online newswires. FNMG and its affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT a registered broker/dealer/analyst/adviser, holds no investment
licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's
market updates, news alerts and corporate profiles are NOT a solicitation or
recommendation to buy, sell or hold securities. The material in this release is
intended to be strictly informational and is NEVER to be construed or
interpreted as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed financial
professional before considering any level of investing in stocks. The companies
that are discussed in this release may or may not have approved the statements
made in this release. Information in this release is derived from a variety of
sources that may or may not include the referenced company's publicly
disseminated information. The accuracy or completeness of the information is not
warranted and is only as reliable as the sources from which it was obtained.
While this information is believed to be reliable, such reliability cannot be
guaranteed. FNMG disclaims any and all liability as to the completeness or
accuracy of the information contained and any omissions of material fact in this
release. This release may contain technical inaccuracies or typographical
errors. It is strongly recommended that any purchase or sale decision be
discussed with a financial adviser, or a broker-dealer, or a member of any
financial regulatory bodies. Investment in the securities of the companies
discussed in this release is highly speculative and carries a high degree of
risk. FNMG is not liable for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. This release is not without bias, and
is considered a conflict of interest if compensation has been received by FNMG
for its dissemination. To comply with Section 17(b) of the Securities Act of
1933, FNMG shall always disclose any compensation it has received, or expects to
receive in the future, for the dissemination of the information found herein on
behalf of one or more of the companies mentioned in this release. For current
services performed FNMG has been compensated one thousand nine hundred dollars
for Kasten, Inc. coverage by
a non-affiliated third party. FNMG HOLDS NO SHARES OF Kasten, Inc.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and FNMG undertakes no obligation to update such
statements.
|
